ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “add” rating reissued by investment analysts at Peel Hunt in a report released on Tuesday,Digital Look reports. They presently have a GBX 270 target price on the stock. Peel Hunt’s price target suggests a potential upside of 17.19% from the stock’s previous close.
A number of other analysts have also issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 315 price objective on shares of ConvaTec Group in a research note on Wednesday, April 8th. UBS Group restated a “buy” rating and issued a GBX 375 target price on shares of ConvaTec Group in a research note on Monday, May 18th. Citigroup lowered their price target on shares of ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating for the company in a report on Monday, May 18th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 300 price target on shares of ConvaTec Group in a research note on Monday, June 8th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 340 price objective on shares of ConvaTec Group in a research report on Tuesday, April 21st. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, ConvaTec Group has a consensus rating of “Moderate Buy” and an average price target of GBX 306.
Read Our Latest Research Report on CTEC
ConvaTec Group Trading Up 2.2%
Insider Transactions at ConvaTec Group
In related news, insider Jonny Mason acquired 50,000 shares of ConvaTec Group stock in a transaction on Tuesday, May 26th. The shares were purchased at an average cost of GBX 201 per share, for a total transaction of £100,500. 0.98% of the stock is owned by corporate insiders.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Read More
- Five stocks we like better than ConvaTec Group
- 3 Drone Stocks That Should Soar After the Summer Slump
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
